Contraception
Conditions
Interventions
A total of 955 women will participate on the study, and 351 in the group of implant, 254 in the group of short acting reversible methods (oral contraceptives, injectables and vaginal ring), 175 in the
Z30.0
Z30.4
Z30.5
Sponsors
Hospital da Mulher Professor Doutor José Aristodemo Pinotti - Centro de Atenção Integral à Saúde da Mulher - CAISM/ Unicamp
Hospital da Mulher Professor Doutor José Aristodemo Pinotti - Centro de Atenção Integral à Saúde da Mulher - CAISM/ Unicamp
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Women between the ages of 18 and 40; Literacy; New Implanon acceptors; TCu380A IUDs; SIU-LNG and short-term methods like combined pill, injectable and vaginal ring
Exclusion criteria
Exclusion criteria: history of tromboembolism; uterine malformations; blood hipertension; diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: Acceptability of the LNG-IUS and the Implanon when offered as a free choice and without cost to women in the public sector must be higher than the TCu380A IUD: almost of the 70% of new contraceptives available at the Outpatient clinic will be choose a LNG-IUS and Implanon, whereas 30% of women will choose TCu380A IUD; and could be higher when compared to those who choose short acting reversible contraceptive methods (oral contraceptives, injectables, and vaginal ring) (70% vs. 40%);Outcome observed1: We enrolled a total of 609 women. A total of 358/609 women (58.8%) choose the ENG-implant and 251/609 (41.2%) choose SARC methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: The continuation rate of the LNG-IUS, Implanon and TCu 380ª IUD, when offered as free choice and without cost to women at the public sector, may be similar: almost 80% of continuation up to the first year and 60% up to the second year; and must be higher when compared to those who choose SARC methods (oral contraceptives, injectables, and vaginal ring) (80% vs. 40%);Outcome observed 2: We observed a peak of discontinuation of the ENG-implant users at month 15 of the study whereas among users of the SARC methods the high discontinuation occurs at months 3 and 6. Continuation rate was higher among users of the ENG-implant (89.9% [322/358] and 75.4% [270/358]) when compared to users of SARC methods (27.2% [69/251] and 15.9% [40/251]) up to one and two years after the study initiation, respectively. ;Expected outcome 3: The main reasons for removal for each intrauterine method must be irregular bleeding, pain and expulsion, whereas for Implanon the main reason of discontinuation must be irregular bleeding; ;Outcome observed 3: The main reasons for discontinuation among users of the LNG-IUS and the TCu380A IUD were irregular bleeding, pain and expulsion whereas for the Implanon the main reason for discontinuation was irregular bleeding; ;Expected outcome 4: The main reason of discontinuation of the SARC methods (combined oral contraceptives, injectables and vaginal ring) may be irregular bleeding, dizziness, pain and abdominal pain;Outcome observed 4: The main reason of discontinuation of the SARC methods (combined oral contraceptives, injectables and vaginal ring) were irregular bleeding, dizziness, pain and abdominal pain, and acne;;Expected outcome 5: The women´s groups must be satisfied with the chosen contraceptive in a proportion of 80% for the LARCs and 60% for the SARC methods.;Outcome observed 5: Satisfaction was high in both group of users; however, users of the ENG-implant reported satisfaction rate of 83.2% and 82.2% when compared to 92.8% | — |
Countries
Brazil
Contacts
Public ContactLuis;Adriana Bahamondes;Costa
Hospital da Mulher Professor Doutor José Aristodemo Pinotti - Centro de Atenção Integral à Saúde da Mulher - CAISM/ Unicamp;Centro de Pesquisa em Saúde Reprodutiva de Campinas
Outcome results
None listed